Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 2Lymphoma 2Breast Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Leukemia 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 35Rituximab 33venetoclax 24ibrutinib 14Vincristine 14Prednisone 14Doxorubicin 14Gemcitabine 13pembrolizumab 12fludarabine 12Bendamustine Hydrochloride 11Etoposide 10obinutuzumab 9Filgrastim 9Dexamethasone 9Bortezomib 9fludarabine phosphate 8Mycophenolic Acid 8Drug Therapy 8ofatumumab 7Whole-Body Irradiation 7Sirolimus 7Peripheral Blood Stem Cell Transplantation 7Methotrexate 7Busulfan 7Therapeutics 6Radiotherapy 6Mesna 6Lenalidomide 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × valspodar × Lymphoid × Clear all
NCT00001383 2008-03-04

A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
52 enrolled
BreastGenitourinaryGynecologicLymphoid

Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡